肝动脉化疗栓塞术联合卡瑞利珠单抗对中晚期肝癌的治疗效果评估

肝脏 ›› 2025, Vol. 30 ›› Issue (4): 441-445.

肝动脉化疗栓塞术联合卡瑞利珠单抗对中晚期肝癌的治疗效果评估

龙春梅, 陈定贵, 郑中伟, 张秀军

213000 江苏常州市第三人民医院消化肿瘤科(龙春梅,陈定贵,郑中伟),肝炎科(张秀军)

收稿日期:2024-10-09 出版日期:2025-04-30 发布日期:2025-06-17
通讯作者: 张秀军,Email: xiujun_z@163.com
基金资助:
南京医科大学常州医学中心科研项目(CMCC202311)

An evaluation of the therapeutic effects of transarterial chemoembolization combined with carrelizumab on advanced hepatocellular carcinoma

LONG Chun-mei¹, CHEN Ding-gui¹, ZHENG Zhong-wei¹, ZHANG Xiu-jun²

1. Department of Digestive Oncology, Changzhou Third People's Hospital), Jiangsu 213000, China;
2. Department of Hepatitis, Changzhou Third People's Hospital), Jiangsu 213000,China

Received:2024-10-09 Online:2025-04-30 Published:2025-06-17
Contact: ZHANG Xiu-jun,Email: xiujun_z@163.com

摘要/Abstract

摘要： 目的探讨肝动脉化疗栓塞术(TACE)联合卡瑞利珠单抗对中晚期肝癌的治疗效果。方法选取2020年1月—2022年10月在常州市第三人民医院治疗的中晚期肝癌患者,共108例,随机平均分为两组。对照组行TACE,观察组接受TACE联合卡瑞利珠单抗治疗。治疗3个月后进行评估,并比较两组2年随访的总生存期(OS)和生存率。结果观察组和对照组疗效分别为70.37%和50.00%(P<0.05);经治疗,观察组CD3⁺,CD4⁺,CD8⁺分别为(39.21±5.13)、(27.21±4.04)和(18.74±2.35)%,且免疫功能和肝功能优于对照组,肿瘤标志物显著降低(P<0.05)。观察组和对照组不良反应发生率为24.07%和27.78%(P>0.05)。观察组平均OS为21.46(20.34,22.59)月,生存率为66.67%(36/54),均高于对照组(P<0.05)。结论中晚期肝癌治疗中应用TACE联合卡瑞利珠单抗,有助于提高疗效。

关键词: 肝动脉灌注化疗栓塞术, 卡瑞利珠单抗, 中晚期肝癌, 临床疗效, 免疫功能

Abstract: Objective To investigate the therapeutic effects of transarterial chemoembolization (TACE) combined with carrelizumab on advanced hepatocellular carcinoma (HCC). Methods The study involved 108 patients with advanced HCC treated at our hospital from January 2020 to October 2022. Patients were randomly divided into two groups, with 54 patients in each group. The control group was treated with TACE alone, whereas the observation group received a combination treatment of TACE and carrelizumab. The clinical efficacy, immune function, tumor marker levels, and liver function were compared between the two groups at three months post-treatment. Adverse reactions happened during treatment were also recorded. All patients were followed up for two years to document OS and overall survival rates. Results The overall effective treatment rate for the observation group and the control group was 70.37% (38/54) and 50.00% (27/54), respectively (P<0.05). The contents of CD3⁺, CD4⁺, and CD8⁺ cells were (39.21±5.13)%, (27.21±4.04)%, and (18.74±2.35)%, respectively, indicating better improvements in immune and liver function (P<0.05). The incidence of adverse reactions was 24.07% in the observation group and 27.78% in the control group (P>0.05). The OS in the observation group was 21.46 (20.34, 22.59) months, with a survival rate of 66.67% (36/54), both significantly higher than those in the control group (P<0.05). Conclusion TACE combined with carrelizumab can enhance the clinical efficacy in advanced HCC, improve immune and liver function, and subsequently increase survival rates.

Key words: Transarterial Chemoembolization, Carrelizumab, Advanced Hepatocellular Carcinoma, Clinical Efficacy, Immune Function

龙春梅, 陈定贵, 郑中伟, 张秀军. 肝动脉化疗栓塞术联合卡瑞利珠单抗对中晚期肝癌的治疗效果评估[J]. 肝脏, 2025, 30(4): 441-445.

LONG Chun-mei, CHEN Ding-gui, ZHENG Zhong-wei, ZHANG Xiu-jun. An evaluation of the therapeutic effects of transarterial chemoembolization combined with carrelizumab on advanced hepatocellular carcinoma[J]. Chinese Hepatolgy, 2025, 30(4): 441-445.

/ 推荐

参考文献

[1] Obi S, Kanda M, Ooka Y, et al. The incidence of all organ malignancies and overall survival of patient with sustained virological response of HCV-comparable to SMR (standardized mortality ratio) of Japan general population[J]. Hepatol Int, 2023, 17(3):562-572.
[2] 何龙, 阎雄. 中晚期肝癌转化治疗方法的应用进展[J]. 山东医药,2023,63(3):108-111.
[3] 陈海琳, 杨涛, 周云. 原发性肝癌患者双源CT全肝灌注成像特点及对TACE术后残余病灶的评估价值[J]. 实用肝脏病杂志,2024,27(5):769-772.
[4] Ye T W, Wang D D, Lu W F, et al. Survival benefit of adjuvant transcatheter arterial chemoembolization for patients with hepatocellular carcinoma after anatomical hepatectomy[J]. Expert Rev Gastroenterol Hepatol, 2023, 17(4):395-403.
[5] Hou C, Xiong B, Zhou L, et al. Transarterial chemoembolization with molecular targeted therapies plus camrelizumab for recurrent hepatocellular carcinoma[J]. BMC Cance, 2024, 24(1):387.
[6] Zhang C, Qin S, Zuo Z. Immune-related myocarditis in two patients receiving camrelizumab therapy and document analysis[J]. J Oncol Pharm Pract, 2022, 28(6):1350-1356.
[7] 中华人民共和国卫生和计划生育委员会医政医管局. 原发性肝癌诊疗规范(2017年版)[J]. 中华消化外科杂志,2017,16(7):635-647.
[8] 邵梦扬. 实体瘤疗效综合评定标准[C]. 全国第三届中医肿瘤学术年会论文集.北京:中国中医药学会,2001:64-66.
[9] 卢实春. 精准医疗时代转化序贯外科方案会成为晚期肝癌治疗的有效选择吗？. 中华肝胆外科杂志,2022,28(01) : 1-6.
[10] 张北光, 刘颖, 于占杰, 等. 老年中晚期原发性肝癌患者介入治疗的临床效果[J]. 中国老年学杂志,2023,43(19):4665-4667.
[11] 冉君, 屈献乐, 肖彬彬, 等. 肝细胞癌免疫微环境与免疫抑制治疗的研究进展[J]. 肝脏,2022,27(7):825-828.
[12] Ding X, Hua Y J, Zou X, et al. Camrelizumab plus famitinib in patients with recurrent or metastatic nasopharyngeal carcinoma treated with PD-1 blockade: data from a multicohort phase 2 study[J]. EclinicalMedicine, 2023, 61:102043.
[13] 徐军红, 姚红兵, 王雪尧, 等. FOLFOX-肝动脉灌注化疗联合应用仑伐替尼和程序性死亡受体1抑制剂治疗中晚期肝癌[J]. 实用医学杂志,2024,40(6):762-767.
[14] Mikhail A S, Negussie A H, Mauda-Havakuk M, et al. Drug-eluting embolic microspheres: state-of-the-art and emerging clinical applications. Expert Opin Drug Deliv[J]. 2021, 18(3):383-398.
[15] Li T, Shi Q, Liu J, et al. Donafenib-loaded callispheres beads embolization in a VX2 liver tumor: investigating efficacy, safety, and improvement of tumor angiogenesis after embolization[J]. J Hepatocell Carcinoma, 2021, 8:1525-1535.
[16] 杜蔚然, 郭成祥, 白雪莉, 等. 经导管肝动脉栓塞化疗联合系统性药物治疗肝细胞癌的研究进展. 中华肝胆外科杂志,2023,29(12) : 949-955.
[17] Basra M, Patel H, Biglione A. Intra-arterial chemotherapy in patients with metastatic or locally aggressive pancreatic adenocarcinoma: a scoping review[J]. Cureus, 2024, 16(5):e60696.
[18] Pu Y, Ji Q. Tumor-associated macrophages regulate PD-1/PD-L1 immunosuppression[J]. Front Immunol, 2022, 13:874589.
[19] Zhong L, Liu X, Li Z, et al. Recurrent gallbladder carcinoma with pMMR/MSS achieved a complete response following camrelizumab combined with apatinib: a case report[J]. Front Oncol, 2022, 11:783158.
[20] 杜尚云, 翁莉, 武敏. TACE联合卡瑞利珠单抗治疗中晚期原发性肝癌患者临床疗效研究[J]. 实用肝脏病杂志,2023,26(1):116-119.
[21] Zhang J X, Chen Y X, Zhou C G, et al. Efficacy and safety of the combination of transarterial chemoembolization with camrelizumab plus apatinib for advanced hepatocellular carcinoma: a retrospective study of 38 patients from a single center[J]. Can J Gastroenterol Hepatol, 2022, 2022:7982118.
[22] 李臻, 李杰, 李鑫, 等. 非侵入性肝纤维化诊断模型对肝癌DEB-TACE术后急性肝功能恶化的预测与生存分析[J]. 临床放射学杂志,2023,42(09):1507-1512.
[23] Yang C, Xu C, Li X, et al. Could camrelizumab plus chemotherapy improve clinical outcomes in advanced malignancy? A systematic review and network meta-analysis[J]. Front Oncol, 2021, 11:700165.
[24] 苏珂, 徐尧阳, 郭露, 等. 肝动脉化疗栓塞联合卡瑞利珠单抗治疗中晚期肝细胞癌的疗效分析[J]. 介入放射学杂志,2022,31(9):865-870.